 To quantify the disease-specific cost burden and healthcare utilization in chronic rhinosinusitis (CRS) patients having endoscopic sinus surgery (ESS)  To differentiate the impacts of revision surgery and nasal polyposis (NP) on one-year total related medical and pharmacy expenditures
 To quantify the disease-specific cost burden and healthcare utilization in chronic rhinosinusitis (CRS) patients having endoscopic sinus surgery (ESS)  To differentiate the impacts of revision surgery and nasal polyposis (NP) on one-year total related medical and pharmacy expenditures
Methods
 The data source was 2012-2015 records from the Blue Health Intelligence database.  Adult patients of working age (18-64 years) having ESS (ethmoidectomy CPT code 31254 or 31255) for CRS and no record of a prior ESS within their plan enrollment were included.  The population with at least one day of medical enrollment beyond the index ESS visit was defined as the survival population and was used for determining revision rates.  The subset of patients with ±12 months of both medical and pharmacy insurance enrollment was defined as the cost population.  The CRS with NP (CRSwNP) cohort was defined as those patients with a NP ICD-9 diagnosis code of 471.xx recorded within -6 to +12 months of their first observed ESS, and the remaining patients comprised the CRS without NP (CRSsNP) cohort.
 Related healthcare utilization was defined as any visit with a primary diagnosis of CRS, acute sinusitis, NP, or any prescription from a therapeutic category commonly used to treat CRS or related comorbidities.  A Kaplan-Meier survival model was utilized to generate product limit estimates of revision surgery rates over time in the survival population by CRSwNP/ CRSsNP cohort.
 The primary outcomes of interest were revision surgery rates and one-year total related medical and pharmacy expenditures by CRSwNP/CRSsNP cohort.
Results
 A total of 86,052 patients met the inclusion criteria for the survival population; 35,203 (41%) were CRSwNP and 50,849 (59%) were CRSsNP. [ Figure 1 ]  The subset comprising the cost population included 23,542 patients (mean age 44; 50% male), of which 9,665 (41%) were CRSwNP and 13,877 (59%) were CRSsNP. [ Figure 1 ]  Comorbid conditions are shown for the cost population in Table 1 , as recorded within the 6 months before and during the index ESS visit. Other than the required CRS diagnosis at the index visit, the most prevalent conditions were deviated septum (60%) and turbinate hypertrophy (57%), as recorded at the ESS visit. [ Table 1 ]  The Kaplan-Meier revision ESS rate estimates were 3.5% in the CRSwNP cohort and 1.6% in the CRSsNP cohort for the first year after surgery, with cumulative rates of patients requiring revision surgery continuing to rise approximately linearly over the 3 years post-index. 
